{
    "ticker": "ATNM",
    "name": "Athenex, Inc.",
    "description": "Athenex, Inc. is a global biopharmaceutical company focused on the development and commercialization of novel therapies for the treatment of cancer. Founded in 2003 and headquartered in Buffalo, New York, Athenex is dedicated to providing innovative and effective treatment options to improve the lives of patients suffering from cancer. The company's core technology platform, known as the 'Oral Chemotherapy' platform, enables the development of oral formulations of chemotherapy agents that are typically administered intravenously, allowing for improved patient compliance and outcomes. Athenex's lead product, KUR-502, is a novel oral formulation of the chemotherapy agent paclitaxel, which is currently in clinical trials for various types of cancer. The company also has a robust pipeline of other oncology products, including those focused on tumor metabolism and immunotherapy. With a commitment to advancing cancer treatment, Athenex collaborates with leading research institutions and has established partnerships to enhance its research capabilities and expand its product offerings. The company's mission is to develop innovative therapies that can address unmet medical needs in oncology, aiming to transform cancer care and improve patient survival rates.",
    "industry": [
        "Biopharmaceuticals",
        "Oncology"
    ],
    "headquarters": "Buffalo, New York, USA",
    "founded": "2003",
    "website": "https://www.athenex.com",
    "ceo": "Johnson Lau",
    "social_media": {
        "twitter": "https://twitter.com/AthenexInc",
        "linkedin": "https://www.linkedin.com/company/athenex/"
    },
    "investor_relations": "https://ir.athenex.com",
    "key_executives": [
        {
            "name": "Johnson Lau",
            "position": "CEO"
        },
        {
            "name": "R. Scott W. Pomerantz",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Products",
            "products": [
                "KUR-502",
                "KUR-503"
            ]
        }
    ],
    "seo": {
        "meta_title": "Athenex, Inc. | Innovative Cancer Therapies",
        "meta_description": "Learn about Athenex, Inc., a biopharmaceutical company focused on innovative therapies for cancer treatment. Explore Athenex's products, mission, and research.",
        "keywords": [
            "Athenex",
            "Biopharmaceuticals",
            "Cancer Treatment",
            "Oncology",
            "KUR-502",
            "Oral Chemotherapy"
        ]
    },
    "faq": [
        {
            "question": "What does Athenex focus on?",
            "answer": "Athenex focuses on developing innovative therapies for the treatment of cancer."
        },
        {
            "question": "Who is the CEO of Athenex?",
            "answer": "Johnson Lau is the CEO of Athenex, Inc."
        },
        {
            "question": "Where is Athenex headquartered?",
            "answer": "Athenex is headquartered in Buffalo, New York, USA."
        },
        {
            "question": "What are Athenex's main products?",
            "answer": "Athenex's main products include KUR-502 and other oncology-focused therapies."
        },
        {
            "question": "When was Athenex founded?",
            "answer": "Athenex was founded in 2003."
        }
    ],
    "competitors": [
        "AMGN",
        "BMY",
        "JNJ",
        "MRK"
    ],
    "related_stocks": [
        "GILD",
        "REGN",
        "VRTX",
        "ABBV"
    ]
}